[go: up one dir, main page]

IN2012DN00719A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00719A
IN2012DN00719A IN719DEN2012A IN2012DN00719A IN 2012DN00719 A IN2012DN00719 A IN 2012DN00719A IN 719DEN2012 A IN719DEN2012 A IN 719DEN2012A IN 2012DN00719 A IN2012DN00719 A IN 2012DN00719A
Authority
IN
India
Prior art keywords
compounds
disorders
compositions
useful
cftr
Prior art date
Application number
Other languages
English (en)
Inventor
Alan S Verkman
Lukmanee Tradtrantip
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IN2012DN00719A publication Critical patent/IN2012DN00719A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN719DEN2012 2009-08-10 2010-08-10 IN2012DN00719A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23274109P 2009-08-10 2009-08-10
PCT/US2010/045052 WO2011019737A1 (fr) 2009-08-10 2010-08-10 Inhibiteurs pyrimido-pyrrolo-quinoxaline dione de la protéine régulatrice de la conductance transmembranaire impliquée dans la fibrose kystique et leurs utilisations

Publications (1)

Publication Number Publication Date
IN2012DN00719A true IN2012DN00719A (fr) 2015-06-19

Family

ID=43586433

Family Applications (1)

Application Number Title Priority Date Filing Date
IN719DEN2012 IN2012DN00719A (fr) 2009-08-10 2010-08-10

Country Status (6)

Country Link
US (1) US8609661B2 (fr)
EP (1) EP2464354B1 (fr)
CN (1) CN102695510A (fr)
CA (1) CA2769847C (fr)
IN (1) IN2012DN00719A (fr)
WO (1) WO2011019737A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48842E1 (en) * 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
KR20150095925A (ko) * 2012-12-19 2015-08-21 노파르티스 아게 Cftr 억제제로서의 트리시클릭 화합물
EP2935278B1 (fr) * 2012-12-19 2017-03-15 Novartis AG Composés tricycliques pour inhiber le canal cftr
GB201905711D0 (en) * 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
CN114948966B (zh) * 2022-04-27 2023-06-20 南京鼓楼医院 一种小分子抑制剂在制备治疗多发性硬化和脓毒症的药物中的应用
CN115998763A (zh) * 2023-01-17 2023-04-25 暨南大学 氯离子及靶向氯离子通道的化合物在调控铁死亡中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751969B1 (fr) * 1996-08-01 1998-12-04 Centre Nat Rech Scient Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
GB9626643D0 (en) * 1996-12-21 1997-02-12 Astra Pharma Prod Compounds
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
ATE440825T1 (de) 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
FR2861304B1 (fr) 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
CA2561560A1 (fr) 2004-03-30 2005-10-13 The Regents Of The University Of California Composes inhibiteurs de cftr contenant des hydrazides et utilisations de ceux-ci
WO2006068928A1 (fr) * 2004-12-20 2006-06-29 Wyeth Pyrrolo[1,2-a]quinoxalin-5-(4h)-yl)sulfonyles and carbonyles et leur utilisation comme agents oestrogeniques
BRPI0809498A2 (pt) * 2007-04-02 2014-09-23 Inst Oneworld Health Compostos inibidores de cftr e seus usos
NZ586271A (en) 2007-12-13 2012-08-31 Vertex Pharma Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator
EP2279029A2 (fr) 2008-03-25 2011-02-02 The Regents of the University of California Inhibiteurs à petite molécule soluble dans l eau du régulateur de conductance transmembranaire de fibrose kystique
EP2288592A2 (fr) 2008-04-04 2011-03-02 The Regents of the University of California Conjugués de composés hydrazide bivalents destinés à inhiber le régulateur de conductance transmembranaire de la mucoviscidose
USRE48842E1 (en) 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor

Also Published As

Publication number Publication date
WO2011019737A1 (fr) 2011-02-17
EP2464354A1 (fr) 2012-06-20
CA2769847A1 (fr) 2011-02-17
EP2464354A4 (fr) 2013-03-27
US8609661B2 (en) 2013-12-17
EP2464354B1 (fr) 2015-04-01
CN102695510A (zh) 2012-09-26
US20120208822A1 (en) 2012-08-16
CA2769847C (fr) 2019-01-08

Similar Documents

Publication Publication Date Title
MX2010010343A (es) Inhibidores solubles en agua de molecula pequeña del regulador de conductancia transmembrana de fibrosis quistica.
IN2012DN00719A (fr)
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
WO2008154251A3 (fr) Anticorps c3b et procédés de prévention et de traitement de troubles associés à un complément
WO2008147797A3 (fr) Modulateurs de canal ionique et leurs procédés d'utilisation
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
WO2006088888A3 (fr) Agents therapeutiques a base d'aptameres utiles dans le traitement de troubles lies au complement
MY172151A (en) Certain chemical entities, compositions and methods
WO2009023509A3 (fr) Combinaisons thérapeutiques utiles pour traiter les maladies liées au cftr
WO2008137633A3 (fr) Procédés de modulation de voies de signalisation homéostatique cellulaires et survie cellulaire
WO2007064857A8 (fr) Formulation de liposomes amphoteres
EP3632444A3 (fr) Antagonistes lfa-1 topiques pour une utilisation dans le traitement localisé de troubles immunitaires associés
EP2134736A4 (fr) Ribothymidines carbocycliques 2', 4' à conformation verrouillée à 5 et 6 éléments destinées à traiter des infections et le cancer
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
WO2008095086A3 (fr) Topiramate plus naltrexone pour le traitement de troubles addictifs
IL190632A0 (en) Biphenyl derivatives and pharmaceutical compositions containing the same
WO2010009478A3 (fr) Compositions et procédés pour traiter des troubles associés à des animaux en surpoids
WO2009146144A3 (fr) Conjugués de composés hydrazide bivalents destinés à inhiber le régulateur de conductance transmembranaire de la mucoviscidose
IN2012DN02471A (fr)
EP2765227A3 (fr) Compositions et procédés permettant d'identifier des troubles du spectre autistique
WO2008144223A3 (fr) Composés triazolyl aminopyrimidine
WO2009158374A3 (fr) Inhibiteurs d’activité akt
WO2009009034A3 (fr) Procédées et compositions utiles dans le traitement de la mucosite
WO2012021800A3 (fr) Inhibiteurs de la caspase utilisés comme agents thérapeutiques contre une lésion neurale ou d'organe et pour l'imagerie